HUTCHMED H1 FY26 net income drops to $15.9 million; revenue rises 0.22% to $278.3 million
HCM•H1 FY26 results
HUTCHMED posted US$15.93 million net income, down from US$454.95 million a year earlier after a 2025 divestment gain. Revenue was US$278.29 million, little changed from a year earlier.
Cash position and China sales
Cash, cash equivalents, and short-term investments totaled US$1.37 billion at June 30, 2026.
Management highlighted China in-market sales up 32% to US$94.4 million, citing improved salesforce productivity after last year’s streamlining.
Segment and product performance
Oncology/Immunology revenue rose 13% to US$162.32 million, driven by ELUNATE revenue up 40% to US$47.1 million.
